President and Chief Executive Officer
In 1992, Mr. White began building a portfolio of service companies in Houston, Texas. Mark’s ability to design, develop, and implement stable and efficient business models positioned his companies as industry leaders.
In 2008, Mr. White began focusing his business interests on the evolving healthcare industry. He immediately aligned his business interests with Nexalin Technology Inc.
Mr. White now leads the outstanding growth and development that Nexalin Technology has experienced over the last 7+ years. He is involved and instrumental in every aspect of the company including the development and understanding of Nexalin’s future in Opiate addiction treatment community. From owning and operating his own clinics and addiction centers, where he has seen first-hand the positive results the technology achieves, he has provided significant contributions to the corporate marketing strategy, manufacturing and FDA compliance, as well as coordinating international clinic trials.
Mr. White is an experienced and well-respected trainer and presenter internationally on the subject of “Brain Based Health” and “Brain Based Recovery”. He is a thought leader in the application of brain stimulation and its ability to address mental health and addiction issues in the United States. Mr. White has also appeared on several prominent news and media shows speaking on Nexalin Technology and electrical brain stimulation as a form of drug free treatment for various psychiatric disorders and addiction treatment.
Mr. White has spent the last seven years immersed in the Nexalin Technology and the patient and practitioner community. In 2010, Mr. White’s distribution company, iiCOM Strategic, became the first national distribution provider for Nexalin Technology Inc. His development of clinical models utilizing the Nexalin Technology has positioned him as an industry leader in all aspects of Nexalin and its clinical applications across the United States and more recently, China. In January of 2012, Mr. White joined the Nexalin Technology corporate team to oversee operations and the development of a successful business model. In December of 2017 was named President and CEO.
Mr. White has a background as a successful entrepreneur and executive for over 20 years; specializing in the financial performance of service-based technology companies. He has decades of success building teams and implementing effective processes, with an emphasis on organizational development, financial stability and the quality and efficiency of services.
Currently Mr. White is transitioning his focus and responsibilities to a full time commitment with Nexalin Technology. He intends to position the company as a leader in the Neurostimulation and Neuromodulation community.
Vice President Clinical Research
Mr. Bradus, a seasoned healthcare executive, began his career with Schering-Plough (now Merck) in the 1970’s. He has a demonstrated record of success in all commercial functions including sales, marketing, production, finance, and research and development.
While he has been successful in both large and small companies, Mr. Bradus is passionate about building businesses from start-up to brand leadership. Under his leadership in previous positions, sales growth has increased an average of 600% accompanied with annual margin escalation.
Mr. Bradus is a performance driven senior executive with an extensive record of success in achieving results. He has a unique dual focus on profits and people. Mr. Bradus lectures in the corporate arena on strategy development based on consumer trends. He has a particular strength in the application of innovative strategies that create product distinction in the marketplace.
Mr. Bradus plays a key role in the design and implementation of the clinical trial models that will launch Nexalin into the mainstream medical market. His personal opinion is that Nexalin will become a global leader in the drug-free treatment community.
Mr. Bradus is know by customers, superiors, peers and subordinates for conducting business with the highest level of integrity. The Nexalin clinical trial methodology is a reflection of his integrity.
He has degrees in economics, finance, and accounting.
Dr. Agresti was raised in New Jersey and came to Florida after completing medical training. He attended Tulane University in New Orleans, LA for premed. The Chicago Medical School for medical school, and completed his Residency in Psychiatry at Roosevelt Hospital in New York City. He is Board Certified in the Practice of Psychiatry.
He has been in private practice in West Palm Beach, FL for 20 years and has been on the staff of Columbia Hospital and several Addiction Treatment centers. He served as Chairman of the Department of Psychiatry at Columbia Hospital and medical director for the various treatment centers.
Dr Agresti’s practice focuses on the treatment of mental illness addictions and dual diagnosis. He has expanded his addictions practice to include outpatient detoxification from both drugs and alcohol. His patient population includes both children and adults.
Dr. Schuder is Board Certified by the American Board of Psychiatry and Neurology. She is a founding member and vice president of the World Society of Antiaging Medicine (WOSAAM), a founding member of the International Hormone Society, and a member of the International Society of Psychoneuroendocrinology (ISPNE), and the American Society of Addiction Medicine and a Diplomate of the American Board of Anti-Aging Medicine.
Dr. Schuder has made it her mission to educate doctors about her common-sense methods in providing a holistic, pro-health approach to patient care, particularly in psychiatry . She also devotes time to lecturing physicians at a variety of international venues on topics related to the mind and emotions and the major life altering impact of hormones, nutrients and toxins. Dr. Schuder also takes the time to teach medical students who rotate through her unique psychiatric practice.
Dr. Schuder provides total patient care through a balanced treatment approach by merging the best of traditional medicine with science-based alternative solutions to provide excellence in patient care. She recently added a Nexalin, a unique transcranial electrostimulation device that provides significant, enduring improvements in patients with depression, anxiety and insomnia.
Dr. Irene Cergnul completed her post-graduate training at Bronx Lebanon Hospital Center in New York and after her final year as Chief Resident was recruited as Assistant Professor in the Department of Family Medicine. She worked as the Medical Director in the in-patient service and also taught residents in training for the next four years. She was a Research Coordinator involving multiple studies on HIV, depression, as well as neuropathy, and is a co-author on several publications.
Dr. Cergnul then transitioned to Montefiore Medical Center at the Substance Abuse Treatment Program where she provided direct medical care to patients, as the Director of HIV Services, and also held Assistant Professorship positions in both the Departments of Family Medicine and Psychiatry. She taught Family Medicine residents, Psychiatry residents and fellows in Addiction Psychiatry.
Dr. Cergnul is Board Certified in Family medicine as well as Addiction Medicine and is currently the Medical Director at Turning Point addiction treatment facility in North Jersey. She has been involved with the field of addiction medicine, HIV care and Psychiatry for the last 12 years. Her private practice focuses on novel modalities used in treating addiction and dual diagnosis patients, both adolescent and adults.
Dr. White is the Clinical Director of Unique MindCare in Houston, Texas. She is recognized as an industry leader in the development of a brain based approach to support neurobehavioral wellness. Dr. White has specialized in the diagnosis and treatment of functional brain disorders for more than twenty years. She is a Fellow, past President and Board member of the International Society for Neurofeedback and Research (ISNR), a Certified EEG Fellow of the Biofeedback Certification International Alliance (BCN) and a QEEG Diplomate and member of the Quantitative EEG Certification Board. Dr. White is a licensed Clinical Psychologist in the State of Texas as well as a Licensed Marriage and Family Therapist and Advanced Addictions Counselor.
Dr. White is a pioneer in the practical application of neuroscientific research to clinical practice, including the extension of advanced brain based therapies to all psychiatric mood disorders including Post-Traumatic Stress, Autism and Addictions. She is a frequent presenter of her work at conferences, including the American Academy of Anti-Aging Medicine, the International Society for Neurofeedback and Research, the Association for Applied Psychophysiology and Biofeedback, FutureHealth, and the National Academy of Neuropsychology. She also serves as a consulting editor of the Journal of Neurotherapy (Taylor and Francis).
Dr White has dedicated 3 years to the development of the clinical application of the Nexalin Therapy. Her research and clinical data on the use of Nexalin Therapy has been presented at International conferences.
Dr. Hu is currently in private practice, with a specialty in General Ophthalmology, which consists of both medical and surgical aspects including use of lasers, in Parma, Ohio: He is also a member of the Board of Directors and an Advisor to Enlighten Technologies Inc. of Laguna Hills California, a company developing a surgical machine for cataract surgery with newly patented technology.
Dr. Hu previously was a member of the NRAGT Board of Advisors, a parent advocacy group trying to increase classes, programs and clubs to challenge the gifted, talented kids of North Royalton, Ohio; a Member of the Board of Advisors of QMS Inc., a company manufacturing and marketing scale control systems and technology to business and industry in Cleveland, Ohio; and Co-Director of Ion-X International, LLC in Huron, Ohio, a company manufacturing, marketing and distributing copper/silver ionization systems and technology to business and industry.
Dr. Hu was awarded his Chemical Engineering degree in June, 1979 in conjunction with the MIT School of Chemical Engineering Practice, Cambridge, Massachusetts, with an emphasis on practical problem solving and independent research projects. Dr. Hu was awarded his Doctorate of Medicine in May, 1983 from Case Western Reserve in Cleveland, Ohio, with an emphasis in applied medical research. Dr. Hu did his Post-Doctorate Resident training in ophthalmology at the Kresge Eye Institute, Wayne State University, Detroit, Michigan. He is the co-developer of a PCL implantation technique in the absence of capsular or zonular support. His technical paper won the First Prize in the Kresge Residence Day competition for best research project and presentation.